- Conditions
- Acne Vulgaris
- Interventions
- IDP-120 Gel, IDP 120 Component A Gel, IDP 120 Component B Gel, IDP 120 Vehicle Gel
- Drug
- Lead sponsor
- Bausch Health Americas, Inc.
- Industry
- Eligibility
- 9 Years and older
- Enrollment
- 364 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2015 – 2016
- U.S. locations
- 20
- States / cities
- Encino, California • Lake Mary, Florida • Miami, Florida + 15 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 2857–2880
of 5,572
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Lymphoma, Non-Hodgkin
- Interventions
- SB-485232, Rituximab
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2010
- U.S. locations
- 2
- States / cities
- Chicago, Illinois • Indianapolis, Indiana
- Conditions
- HIV Infection
- Interventions
- abacavir/lamivudine/zidovudine, tenofovir
- Drug
- Lead sponsor
- ViiV Healthcare
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2004
- U.S. locations
- 27
- States / cities
- Los Angeles, California • San Rafael, California • Fort Lauderdale, Florida + 22 more
- Conditions
- Metastatic Cancer, Cancer, Solid Tumor
- Interventions
- BP31510 monotherapy, BP31510 in combination with chemotherapy
- Drug
- Lead sponsor
- BPGbio
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 97 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2017
- U.S. locations
- 3
- States / cities
- Sunnyvale, California • New York, New York • Houston, Texas
- Conditions
- Multiple Myeloma
- Interventions
- Ascorbate, Melphalan
- Other · Drug
- Lead sponsor
- Christopher Strouse
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2025
- U.S. locations
- 1
- States / cities
- Iowa City, Iowa
- Conditions
- Oropharyngeal Cancer
- Interventions
- Toripalimab, Carboplatin, Paclitaxel
- Drug
- Lead sponsor
- University of Chicago
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2033
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Overactive Bladder, Urinary Tract Infections
- Interventions
- Periprocedural Antibiotics, Extended Antibiotics, Injection of OnabotulinumtoxinA (BTX-A)
- Drug · Procedure
- Lead sponsor
- Vanderbilt University Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 22 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2022
- U.S. locations
- 1
- States / cities
- Nashville, Tennessee
- Conditions
- Age-Related Macular Degeneration
- Interventions
- Avastin, Photodynamic Therapy (PDT), Preservative-Free Triamcinolone Acetonide (TAC-PF)
- Drug · Procedure
- Lead sponsor
- National Eye Institute (NEI)
- NIH
- Eligibility
- 50 Years and older
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007
- U.S. locations
- 11
- States / cities
- Fort Lauderdale, Florida • Orlando, Florida • Pensacola, Florida + 8 more
- Conditions
- Healthy Volunteer, Opioid-use Disorder
- Interventions
- INDV-2000, Placebo, SUBOXONE® sublingual film
- Drug
- Lead sponsor
- Indivior Inc.
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 64 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2023
- U.S. locations
- 3
- States / cities
- Baltimore, Maryland • DeSoto, Texas • San Antonio, Texas
- Conditions
- Melanoma
- Interventions
- MSB0010445 (0.3 milligram per kilogram [mg/kg]), MSB0010445 (1.0 mg/kg), MSB0010445 (1.8 mg/kg), MSB0010445 (2.4 mg/kg), Stereotactic Body Radiation Therapy (SBRT)
- Drug · Radiation
- Lead sponsor
- EMD Serono
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2015
- U.S. locations
- 1
- States / cities
- Rockland, Massachusetts
- Conditions
- Acne
- Interventions
- Adapalene/BPO Gel, Moisturizer SPF 30, Foam Wash
- Drug · Other
- Lead sponsor
- Galderma R&D
- Industry
- Eligibility
- 9 Years and older
- Enrollment
- 81 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2014
- U.S. locations
- 5
- States / cities
- Boynton Beach, Florida • Nashville, Tennessee • Carrollton, Texas + 2 more
- Conditions
- Locally Advanced Solid Tumor
- Interventions
- AN2025, AN0025, Atezolizumab 1200 mg in 20 ML Injection
- Drug
- Lead sponsor
- Adlai Nortye Biopharma Co., Ltd.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 47 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2025
- U.S. locations
- 5
- States / cities
- Aurora, Colorado • Lake Mary, Florida • New Brunswick, New Jersey + 2 more
- Conditions
- Head and Neck Cancer
- Interventions
- Induction chemotherapy, cisplatin, fluorouracil, low-LET cobalt-60 gamma ray therapy
- Drug · Radiation
- Lead sponsor
- SWOG Cancer Research Network
- Network
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 68 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1996 – 2005
- U.S. locations
- 18
- States / cities
- Little Rock, Arkansas • Los Angeles, California • Denver, Colorado + 10 more
- Conditions
- Lymphoma, Primary Central Nervous System Lymphoma
- Interventions
- Pembrolizumab, Methotrexate, Temozolomide, Rituximab
- Drug
- Lead sponsor
- Dana-Farber Cancer Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 2
- States / cities
- Boston, Massachusetts
- Conditions
- HIV Infections
- Interventions
- Ritonavir, Nelfinavir mesylate, Saquinavir, Delavirdine mesylate
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 16 Years and older
- Enrollment
- 375 participants
- Healthy volunteers
- Healthy volunteers not accepted
- U.S. locations
- 2
- States / cities
- Los Angeles, California • Brookline, Massachusetts
- Conditions
- Melanoma (Skin), Skin Cancer
- Interventions
- Nivolumab, Surgery to Remove Tumor for Growth of TIL, CD137, Cyclophosphamide, Fludarabine, TIL Infusion, Interleukin-2
- Drug · Procedure · Biological
- Lead sponsor
- H. Lee Moffitt Cancer Center and Research Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 11 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2020
- U.S. locations
- 1
- States / cities
- Tampa, Florida
- Conditions
- PrEP Adherence Monitoring
- Interventions
- tenofovir disoproxil and emtricitabine
- Drug
- Lead sponsor
- Rutgers, The State University of New Jersey
- Other
- Eligibility
- 18 Years to 64 Years · Female only
- Enrollment
- 162 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016 – 2024
- U.S. locations
- 4
- States / cities
- Atlanta, Georgia • Chicago, Illinois • Newark, New Jersey + 1 more
- Conditions
- Healthy Participants
- Interventions
- Atazanavir/Cobicistat, Reyataz Atazanavir, Cobicistat
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years to 49 Years
- Enrollment
- 34 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020
- U.S. locations
- 1
- States / cities
- Austin, Texas
- Conditions
- Coronary Artery Disease
- Interventions
- Hybrid Coronary Revascularization (HCR), Coronary Artery Bypass Grafting (CABG)
- Procedure
- Lead sponsor
- Emory University
- Other
- Eligibility
- Not listed
- Enrollment
- 75 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2018
- U.S. locations
- 1
- States / cities
- Atlanta, Georgia
- Conditions
- Gastrointestinal Cancer
- Interventions
- Cobimetinib, Hydroxychloroquine, Atezolizumab
- Drug
- Lead sponsor
- Columbia University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 27 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2022
- U.S. locations
- 2
- States / cities
- New York, New York • Providence, Rhode Island
- Conditions
- Lymphoma, Follicular, Follicular Lymphoma
- Interventions
- Mosunetuzumab, Polatuzumab vedotin
- Drug
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 34 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2029
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- Hypertension
- Interventions
- Azilsartan medoxomil and chlorthalidone, Chlorthalidone, Azilsartan medoxomil
- Drug
- Lead sponsor
- Takeda
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,711 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2010
- U.S. locations
- 84
- States / cities
- Birmingham, Alabama • Columbiana, Alabama • Tuscaloosa, Alabama + 81 more
- Conditions
- Respiratory Distress Syndrome
- Interventions
- Lucinactant delivered via investigational delivery device, nCPAP
- Drug
- Lead sponsor
- Windtree Therapeutics
- Industry
- Eligibility
- 26 Weeks to 32 Weeks
- Enrollment
- 221 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2019
- U.S. locations
- 22
- States / cities
- Birmingham, Alabama • Little Rock, Arkansas • Loma Linda, California + 18 more
- Conditions
- Solid Tumor, Advanced Solid Tumor
- Interventions
- M4344 10 mg BIW, M4344 20 mg BIW, M4344 40 mg BIW, M4344 80 mg BIW, M4344 160 mg BIW, M4344 300 mg BIW, M4344 450 mg BIW, M4344 700 mg BIW, M4344 1050 mg BIW, M4344 1200 mg BIW, M4344 100 mg BID, M4344 150 mg QD, M4344 250 mg QD, M4344 350 mg QD, M4344 400 mg, M4344 500 mg, Carboplatin
- Drug
- Lead sponsor
- EMD Serono Research & Development Institute, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 97 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2021
- U.S. locations
- 8
- States / cities
- Boston, Massachusetts • Ann Arbor, Michigan • St Louis, Missouri + 4 more